International Urogynecology Journal

, Volume 20, Issue 4, pp 381–385

Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months


    • Department of Obstetrics and GynecologyUniversity of New Mexico School of Medicine
  • Tola Omotosho
    • Department of Obstetrics and GynecologyUniversity of New Mexico School of Medicine
  • Gloria Bachmann
    • New Jersey-Robert Wood Johnson Medical SchoolUniversity of Medicine and Dentistry
  • Franklin Sun
    • Pfizer Inc.
  • Jon D. Morrow
    • Pfizer Inc.
Original Article

DOI: 10.1007/s00192-008-0782-9

Cite this article as:
Rogers, R.G., Omotosho, T., Bachmann, G. et al. Int Urogynecol J (2009) 20: 381. doi:10.1007/s00192-008-0782-9


Improvements in overactive bladder (OAB) symptoms and health-related quality of life (HRQL) were assessed during a 24-week study of tolterodine extended release (TOL ER) in sexually active women with OAB and urgency urinary incontinence (UUI). A 12-week, double-blind, randomized, placebo-controlled trial was followed by a 12-week open-label phase. Sexually active women reported symptoms for ≥3 months. Subjects completed bladder diaries and HRQL measures at baseline and weeks 12 and 24. One hundred sixty-one women received TOL ER for 24 weeks. Women reported significant improvements in all end points at week 12 that were maintained or improved at 24 weeks. At week 24, 70% of subjects reported no UUI episodes. TOL ER resulted in improvements in OAB symptoms and HRQL that were maintained or greater with 6 months of use. Long-term compliance with OAB pharmacotherapy may be important for optimal treatment outcomes.


Overactive bladderPatient-reported outcomesUrgency urinary incontinenceUrinary incontinenceWomen

Copyright information

© The International Urogynecological Association 2008